Learn More

Visit Capella to learn more about the scientific progress we are making as we translate the science of RNAi into human clinical experience and ultimately towards the development of innovative medicines for patients.

Latest News

Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemophilia and Other Bleeding Disorders at 54th American Society of Hematology (ASH) Annual Meeting

Culture

"Logic will get you from A to B. Imagination will take you everywhere" — Albert Einstein

We are a growing biopharmaceutical company with deep resources focused on a remarkable biological breakthrough called RNAi that could be transformative for medicine and could dramatically improve the lives of patients. We have demonstrated the ability to harness RNAi for therapeutic gene silencing, including the first-ever human proof of concept for an RNAi therapeutic and we won't stop there.

We are a growing community of scientific and business leaders and we thrive on interacting and challenging each other (almost all the time).

We come together from dozens of countries. We speak over 20 languages. We have diverse educations, backgrounds, skill sets, lives, and turns of phrase. We listen. We laugh (out loud) at ourselves. We know what to take seriously. We work incredibly hard (because we want to). We do many things at a time, but have a resolute focus on creating new medicines.

Vision: Harnessing a revolution in biology for human health®

Alnylam was founded in 2002 on a bold vision - a vision which remains firmly in place today. We are executing on our mission of building a top-tier biopharmaceutical company founded on RNAi. Our commitment to innovation and excellence is reflected in everything we do, earning us a leadership position in both the science and business of RNAi therapeutics that is recognized worldwide.

Andrew Sprague
Scientist, Biology
Joined Alnylam in July 2003

"Alnylam promotes an extremely innovative mentality among its employees. Because the company is still growing, we all have a bigger role to play in the company's success. Therefore, I am constantly pushed to explore new ideas and develop new processes. In addition, I have the opportunity to work alongside people who have decades of experience in a variety of fields, therefore providing me with incredible insights and perspectives."

Tim Buck
Senior Associate, Business Planning and Program Management
Joined Alnylam in January 2007

"Alnylam challenges me to continue learning and become a better thinker. Through various company events such as the scientific seminars or our journal club, I am always encouraged to expand my knowledge in a variety of areas. While I could easily spend my entire day in the lab only focusing on my own projects, I am encouraged to explore all the exciting things that are happening around me. Also, I work with some really experienced scientists whose doors are always open if I have any questions or simply want to pick their brains."

Rena Denoncourt
Program Manager
Joined Alnylam in June 2007

"As a program manager, I work at the intersection of science and business, which gives me the opportunity interact with people from all areas of the company. Everyone here is incredibly passionate about the work we do and sincerely believes in the promise of RNAi. We are all committed to playing our part in the translation of this technology into real products."